Recombinant Zika virus subunits are immunogenic and efficacious in mice

mSphere

Volumn 3, Issue 1, 2018, Pages

  To, Albert ^a   Medina, Liana O ^a   Mfuh, Kenji O ^a   Lieberman, Michael M ^a   Wong, Teri Ann S ^a   Namekar, Madhuri ^a   Nakano, Eileen ^a   Lai, Chih Yun ^a   Kumar, Mukesh ^a   Nerurkar, Vivek R ^a   Lehrer, Axel T ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Recombinant; Subunit; Vaccine; Zika virus

Indexed keywords

EID: 85041543324     PISSN: None     EISSN: 23795042     Source Type: Journal    
DOI: 10.1128/mSphere.00576-17     Document Type: Article

References (61)

1. Dick GW, Kitchen SF, Haddow AJ. 1952. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46:509-520. https:// doi.org/10.1016/0035-9203(52)90042-4
2. Smithburn KC, Taylor RM, Rizk F, Kader A. 1954. Immunity to certain arthropod-borne viruses among indigenous residents of Egypt. Am J Trop Med Hyg 3:9-18. https://doi.org/10.4269/ajtmh.1954.3.9
3. Smithburn KC. 1952. Neutralizing antibodies against certain recently isolated viruses in the sera of human beings residing in East Africa. J Immunol 69:223-234
4. Macnamara FN. 1954. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans R Soc Trop Med Hyg 48:139-145. https://doi.org/10.1016/0035-9203(54)90006-1
5. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C, Guillaumot L, Griggs A, Bel M, Lambert AJ, Laven J, Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB. 2009. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 360:2536-2543. https://doi.org/10.1056/ NEJMoa0805715
6. Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E, Mallet HP, Musso D, Fontanet A, Neil J, Ghawché F. 2016. Guillain-Barre syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387:1531-1539. https://doi.org/ 10.1016/S0140-6736(16)00562-6
7. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, Baudouin L, Mallet H, Musso D, Ghawche F. 2014. Zika virus infection complicated by Guillain-Barre syndrome-case report, French Polynesia, December 2013. Euro Surveill 19. https://doi.org/10.2807/1560-7917.ES2014.19.9 .20720
8. Cardoso CW, Paploski IA, Kikuti M, Rodrigues MS, Silva MM, Campos GS, Sardi SI, Kitron U, Reis MG, Ribeiro GS. 2015. Outbreak of exanthematous illness associated with Zika, chikungunya, and dengue viruses, Salvador, Brazil. Emerg Infect Dis 21:2274-2276. https://doi.org/10.3201/eid2112 .151167
9. Campos GS, Bandeira AC, Sardi SI. 2015. Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 21:1885-1886. https://doi.org/10.3201/eid2110.150847
10. Schuler-Faccini L, Ribeiro EM, Feitosa IM, Horovitz DD, Cavalcanti DP, Pessoa A, Doriqui MJ, Neri JI, Neto JM, Wanderley HY, Cernach M, El-Husny AS, Pone MV, Serao CL, Sanseverino MT, Brazilian Medical Genetics Society-Zika Embryopathy Task. 2016. Possible association between Zika virus infection and microcephaly-Brazil, 2015. MMWR Morb Mortal Wkly Rep 65:59-62. https://doi.org/10.15585/mmwr.mm6503e2
11. Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J, Kolenc M, Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodušek V, Vizjak A, Pižem J, Petrovec M, Avšič Županc T. 2016. Zika virus associated with microcephaly. N Engl J Med 374:951-958. https://doi.org/10.1056/NEJMoa1600651
12. Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL. 2016. Zika and the risk of microcephaly. N Engl J Med 375:1-4. https:// doi.org/10.1056/NEJMp1605367
13. Shapiro-Mendoza CK, Rice ME, Galang RR, Fulton AC, VanMaldeghem K, Prado MV, Ellis E, Anesi MS, Simeone RM, Petersen EE, Ellington SR, Jones AM, Williams T, Reagan-Steiner S, Perez-Padilla J, Deseda CC, Beron A, Tufa AJ, Rosinger A, Roth NM, Green C, Martin S, Lopez CD, deWilde L, Goodwin M, Pagano HP, Mai CT, Gould C, Zaki S, Ferrer LN, Davis MS, Lathrop E, Polen K, Cragan JD, Reynolds M, Newsome KB, Huertas MM, Bhatangar J, Quiñones AM, Nahabedian JF, Adams L, Sharp TM, Hancock WT, Rasmussen SA, Moore CA, Jamieson DJ, Munoz-Jordan JL, Garstang H, Kambui A, Masao C, Honein MA, Meaney-Delman D. 2017. Pregnancy outcomes after maternal Zika virus infection during pregnancy-U.S. Territories, January 1, 2016-April 25, 2017. MMWR Morb Mortal Wkly Rep 66:615-621. https://doi.org/10.15585/mmwr.mm6623e1
14. Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JL, Guimarães KP, Benazzato C, Almeida N, Pignatari GC, Romero S, Polonio CM, Cunha I, Freitas CL, Brandão WN, Rossato C, Andrade DG, Faria DDP, Garcez AT, Buchpigel CA, Braconi CT, Mendes E, Sall AA, Zanotto PM, Peron JP, Muotri AR, Beltrão-Braga PC. 2016. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534:267-271. https://doi .org/10.1038/nature18296
15. Li C, Xu D, Ye Q, Hong S, Jiang Y, Liu X, Zhang N, Shi L, Qin CF, Xu Z. 2016. Zika virus disrupts neural progenitor development and leads to microcephaly in mice. Cell Stem Cell 19:672. https://doi.org/10.1016/j.stem .2016.10.017
16. Miner JJ, Cao B, Govero J, Smith AM, Fernandez E, Cabrera OH, Garber C, Noll M, Klein RS, Noguchi KK, Mysorekar IU, Diamond MS. 2016. Zika virus infection during pregnancy in mice causes placental damage and fetal demise. Cell 165:1081-1091. https://doi.org/10.1016/j.cell.2016.05.008
17. Garcez PP, Loiola EC, Madeiro da Costa R, Higa LM, Trindade P, Delvecchio R, Nascimento JM, Brindeiro R, Tanuri A, Rehen SK. 2016. Zika virus impairs growth in human neurospheres and brain organoids. Science 352:816-818. https://doi.org/10.1126/science.aaf6116
18. Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng'ang'a D, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Agarwal A, Brinkman AL, Cabral C, Chandrashekar A, Giglio PB, Jetton D, Jimenez J, Lee BC, Mojta S, Molloy K, Shetty M, Neubauer GH, Stephenson KE, Peron JP, Zanotto PM, Misamore J, Finneyfrock B, Lewis MG, Alter G, Modjarrad K, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH. 2016. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353:1129-1132. https://doi.org/10.1126/science.aah6157
19. Dowd KA, Ko SY, Morabito KM, Yang ES, Pelc RS, DeMaso CR, Castilho LR, Abbink P, Boyd M, Nityanandam R, Gordon DN, Gallagher JR, Chen X, Todd JP, Tsybovsky Y, Harris A, Huang YS, Higgs S, Vanlandingham DL, Andersen H, Lewis MG, De La Barrera R, Eckels KH, Jarman RG, Nason MC, Barouch DH, Roederer M, Kong WP, Mascola JR, Pierson TC, Graham BS. 2016. Rapid development of a DNA vaccine for Zika virus. Science 354:237-240. https://doi.org/10.1126/science.aai9137
20. Larocca RA, Abbink P, Peron JP, Zanotto PM, Iampietro MJ, Badamchi-Zadeh A, Boyd M, Ng'ang'a D, Kirilova M, Nityanandam R, Mercado NB, Li Z, Moseley ET, Bricault CA, Borducchi EN, Giglio PB, Jetton D, Neubauer G, Nkolola JP, Maxfield LF, De La Barrera RA, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH. 2016. Vaccine protection against Zika virus from Brazil. Nature 536:474-478. https://doi.org/10.1038/ nature18952
21. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, Mitchell CJ, Bowen R, Bunning ML. 2001. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75:4040-4047. https://doi.org/10.1128/JVI.75.9 .4040-4047.2001
22. Kim E, Erdos G, Huang S, Kenniston T, Falo LD, Jr, Gambotto A. 2016. Preventative vaccines for Zika virus outbreak: preliminary evaluation. EBioMedicine 13:315-320. https://doi.org/10.1016/j.ebiom.2016.09.028
23. Reference deleted
24. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, Peters ID, Leung J, Weeks-Levy C, Nakano ET, Humphreys T. 2010. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705-2715. https://doi.org/10.1016/j .vaccine.2010.01.022
25. Lieberman MM, Clements DE, Ogata S, Wang G, Corpuz G, Wong T, Martyak T, Gilson L, Coller BA, Leung J, Watts DM, Tesh RB, Siirin M, Travassos da Rosa A, Humphreys T, Weeks-Levy C. 2007. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 25:414-423. https://doi.org/10.1016/j.vaccine.2006.08.018
26. Jarvi SI, Lieberman MM, Hofmeister E, Nerurkar VR, Wong T, Weeks-Levy C. 2008. Protective efficacy of a recombinant subunit West Nile virus vaccine in domestic geese (Anser anser). Vaccine 26:5338-5344. https:// doi.org/10.1016/j.vaccine.2008.08.011
27. Lehrer AT, Wong TS, Lieberman MM, Humphreys T, Clements DE, Bakken RR, Hart MK, Pratt WD, Dye JM. 16 February 2017. Recombinant proteins of Zaire Ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice. Vaccine https:// doi.org/10.1016/j.vaccine.2017.01.068
28. Lieberman MM, Nerurkar VR, Luo H, Cropp B, Carrion R, Jr, de la Garza M, Coller BA, Clements D, Ogata S, Wong T, Martyak T, Weeks-Levy C. 2009. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 16: 1332-1337. https://doi.org/10.1128/CVI.00119-09
29. Grant A, Ponia SS, Tripathi S, Balasubramaniam V, Miorin L, Sourisseau M, Schwarz MC, Sánchez-Seco MP, Evans MJ, Best SM, García-Sastre A. 2016. Zika virus targets human STAT2 to inhibit type I interferon signaling. Cell Host Microbe 19:882-890. https://doi.org/10.1016/j.chom.2016.05.009
30. Reference deleted
31. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100:6986-6991. https://doi.org/10.1073/pnas.0832193100
32. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney MC, Medits I, Sharma A, Simon-Lorière E, Sakuntabhai A, Cao-Lormeau VM, Haouz A, England P, Stiasny K, Mongkolsapaya J, Heinz FX, Screaton GR, Rey FA. 2016. Structural basis of potent Zika-dengue virus antibody crossneutralization. Nature 536:48-53. https://doi.org/10.1038/nature18938
33. Markoff L. 2000. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 18(Suppl 2):26-32. https://doi.org/10.1016/S0264-410X(00)00038-4
34. Zent O, Beran J, Jilg W, Mach T, Banzhoff A. 2003. Clinical evaluation of a polygeline-free tick-borne encephalitis vaccine for adolescents and adults. Vaccine 21:738-741. https://doi.org/10.1016/S0264-410X(02) 00592-3
35. Gupta AK, Lad VJ, Koshy AA. 2003. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing antiglycoprotein E monoclonal antibodies. Acta Virol 47:141-145
36. Gupta AK, Lad VJ, Koshy AA. 2008. Survival of mice immunized with monoclonal antibodies against glycoprotein E of Japanese encephalitis virus before or after infection with Japanese encephalitis, West Nile, and Dengue viruses. Acta Virol 52:219-224
37. Kreil TR, Maier E, Fraiss S, Eibl MM. 1998. Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein. J Virol 72: 3076-3081
38. Gupta AK, Koshy AA, Lad VJ. 2011. Enhanced protection of mice against Japanese encephalitis virus infection by combinations of monoclonal antibodies to glycoprotein E. Acta Virol 55:165-168. https://doi.org/10 .4149/av_2011_02_165
39. Kawiecki AB, Christofferson RC. 2016. Zika virus-induced antibody response enhances dengue virus serotype 2 replication in vitro. J Infect Dis 214:1357-1360. https://doi.org/10.1093/infdis/jiw377
40. Fagbami AH, Halstead SB. 1986. Antibody-mediated enhancement of Wesselsbron virus in P388D1 cells. Afr J Med Med Sci 15:103-107
41. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, Vanzetta F, Minola A, Jaconi S, Mele F, Foglierini M, Pedotti M, Simonelli L, Dowall S, Atkinson B, Percivalle E, Simmons CP, Varani L, Blum J, Baldanti F, Cameroni E, Hewson R, Harris E, Lanzavecchia A, Sallusto F, Corti D. 2016. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353:823-826. https://doi.org/10 .1126/science.aaf8505
42. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T, Sakuntabhai A, Cao-Lormeau VM, Malasit P, Rey FA, Mongkolsapaya J, Screaton GR. 2016. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol 17:1102-1108. https://doi.org/10.1038/ni.3515
43. Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO, Michael SF, Isern S. 2016. Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunol 5:e117. https://doi.org/10.1038/cti.2016.72
44. Castanha PMS, Nascimento EJM, Braga C, Cordeiro MT, de Carvalho OV, de Mendonça LR, Azevedo EAN, França RFO, Dhalia R, Marques ETA. 2017. Dengue virus-specific antibodies enhance Brazilian Zika virus infection. J Infect Dis 215:781-785. https://doi.org/10.1093/infdis/jiw638
45. Willis E, Hensley SE. 2017. Characterization of Zika virus binding and enhancement potential of a large panel of flavivirus murine monoclonal antibodies. Virology 508:1-6. https://doi.org/10.1016/j.virol.2017.04.031
46. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, García-Sastre A, Krammer F, Lim JK. 2017. Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356:175-180. https://doi .org/10.1126/science.aal4365
47. Fagbami AH, Halstead SB, Marchette NJ, Larsen K. 1987. Cross-infection enhancement among African flaviviruses by immune mouse ascitic fluids. Cytobios 49:49-55
48. Pantoja P, Pérez-Guzmán EX, Rodríguez IV, White LJ, González O, Serrano C, Giavedoni L, Hodara V, Cruz L, Arana T, Martínez MI, Hassert MA, Brien JD, Pinto AK, de Silva A, Sariol CA. 2017. Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. Nat Commun 8:15674. https://doi.org/10.1038/ncomms15674
49. Yang M, Dent M, Lai H, Sun H, Chen Q. 2017. Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine 35:4287-4294. https://doi.org/10 .1016/j.vaccine.2017.04.052
50. Boigard H, Alimova A, Martin GR, Katz A, Gottlieb P, Galarza JM. 2017. Zika virus-like particle (VLP) based vaccine. PLoS Negl Trop Dis 11: e0005608. https://doi.org/10.1371/journal.pntd.0005608
51. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. 2011. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 29:7267-7275. https://doi.org/10.1016/j.vaccine.2011.07.021
52. Khan M, Dhanwani R, Rao PV, Parida M. 2012. Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice. Virus Res 167:236-246. https://doi.org/10.1016/j.virusres.2012.05.004
53. Govindarajan D, Meschino S, Guan L, Clements DE, ter Meulen JH, Casimiro DR, Coller BA, Bett AJ. 2015. Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates. Vaccine 33:4105-4116. https://doi.org/10.1016/j.vaccine.2015.06.067
54. Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, Clements DE, Martyak T, Parks DE, Baldwin S, Reed SG, Coler RN. 2016. A novel synthetic TLR-4 agonist adjuvant increases the protective response to a clinical-stage west Nile virus vaccine antigen in multiple formulations. PLoS One 11:e0149610. https://doi.org/10.1371/journal .pone.0149610
55. Manoff SB, George SL, Bett AJ, Yelmene ML, Dhanasekaran G, Eggemeyer L, Sausser ML, Dubey SA, Casimiro DR, Clements DE, Martyak T, Pai V, Parks DE, Coller BA. 2015. Preclinical and clinical development of a dengue recombinant subunit vaccine. Vaccine 33:7126-7134. https:// doi.org/10.1016/j.vaccine.2015.09.101
56. Namekar M, Kumar M, O'Connell M, Nerurkar VR. 2012. Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay. PLoS One 7:e45851. https://doi.org/10.1371/journal.pone.0045851
57. Wong SJ, Demarest VL, Boyle RH, Wang T, Ledizet M, Kar K, Kramer LD, Fikrig E, Koski RA. 2004. Detection of human anti-flavivirus antibodies with a west Nile virus recombinant antigen microsphere immunoassay. J Clin Microbiol 42:65-72. https://doi.org/10.1128/JCM.42.1.65-72.2004
58. Reference deleted
59. Kumar M, Krause KK, Azouz F, Nakano E, Nerurkar VR. 2017. A guinea pig model of Zika virus infection. Virol J 14:75. https://doi.org/10.1186/ s12985-017-0750-4
60. Blom AG, Hilgers LA. 2004. Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition. Vaccine 23: 743-754. https://doi.org/10.1016/j.vaccine.2004.07.021
61. Verma S, Lo Y, Chapagain M, Lum S, Kumar M, Gurjav U, Luo H, Nakatsuka A, Nerurkar VR. 2009. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: transmigration across the in vitro blood-brain barrier. Virology 385:425-433. https://doi.org/10.1016/j.virol.2008.11.047